R17
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 67
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.380
- INTERFERON_GAMMA_RESPONSE+0.370
- INFLAMMATORY_RESPONSE+0.360
- IL6_JAK_STAT3_SIGNALING+0.340
- INTERFERON_ALPHA_RESPONSE+0.290
- TNFA_SIGNALING_VIA_NFKB+0.240
- IL2_STAT5_SIGNALING+0.210
- CHOLESTEROL_HOMEOSTASIS+0.150
- DNA_REPAIR+0.150
- E2F_TARGETS+0.140
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- MYC_TARGETS_V1-0.340
- ANGIOGENESIS-0.320
- TGF_BETA_SIGNALING-0.290
- MYC_TARGETS_V2-0.260
- UV_RESPONSE_DN-0.260
- P53_PATHWAY-0.230
- PROTEIN_SECRETION-0.220
- COAGULATION-0.190
- NOTCH_SIGNALING-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2712420 | — | — | 0.800 |
| 2 | 5566453e-df41-4aab-8dd0-825efbece954 | — | — | 0.792 |
| 3 | s0122145 | — | — | 0.781 |
| 4 | 1692105e-13d3-45ca-ab70-e6aed396c8c0 | — | — | 0.772 |
| 5 | TCGA-S3-AA17-01A-11R-A41B-07 | — | D | 0.771 |
| 6 | ERR2208913 | — | — | 0.771 |
| 7 | TCGA-A8-A08I-01A-11R-A00Z-07 | — | C | 0.767 |
| 8 | 1f57edd1-3bc9-4eaf-8045-8984d5c7f148 | — | — | 0.760 |
| 9 | b03d2223-38c1-4bb3-be8b-27db05f87b66 | — | — | 0.759 |
| 10 | ERR2208965 | — | — | 0.757 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.380 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.140 | Inavolisib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.060 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.050 | Inavolisib | — uncovered |
| APOPTOSIS | 0.040 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |